This biotech stock is up more than 1,000% since late July. Jefferies thinks there are more gains ahead
The bank initiated the clinical-stage biotechnology firm at a buy rating.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
